Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study

O. Viklicky, I. Zahradka, J. Mares, J. Slatinska, A. Parikova, V. Petr, M. Roder, K. Jaklova, K. Osickova, L. Janousek, P. Hruba

. 2025 ; 38 (-) : 14312. [pub] 20250519

Language English Country Switzerland

Document type Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III

Persistent link   https://www.medvik.cz/link/bmc25015711

Intravenous immunoglobulins (IVIG) are commonly used in peri-transplant desensitization, but evidence supporting their efficacy is limited. We conducted a prospective, randomized single-center, open-label, Phase IIIb non-inferiority clinical pilot trial to compare the efficacy of IVIG (administered at a dose of 3 × 0.5 g/kg) versus no IVIG, in conjunction with rabbit anti-thymocyte globulin (5-7 mg/kg) induction, in pre-sensitized patients with donor-specific antibodies who had negative pre-transplantation Flow- and CDC-crossmatches, between July 2020 and November 2022. The primary endpoint was the rate of efficacy failure, defined as biopsy-proven rejection within 12-month post-transplant. Secondary endpoints included the incidence of rejection at protocol biopsies, evaluated by histology and biopsy-based transcripts diagnostics. Of the screened patients, 53 (72.6%) were excluded due to crossmatch positivity. Ten patients were randomized to the IVIG+, and 7 to the IVIG-arm. The trial was prematurely terminated due to futility at interim analysis. In the IVIG-arm, 3 patients (43%) experienced the primary endpoint compared to none in the IVIG+ arm (p = 0.026). MMDx identified one molecular ABMR in the IVIG+ and 2 in the IVIG-arm in 12-month protocol biopsies. There was one graft loss in the IVIG-arm. The results of this pilot study, although not definitive, do not support the use of IVIG-sparing regimens in HLA-incompatible kidney transplantation (NCT04302805). This study is registered on ClinicalTrials.gov under the identifier NCT04302805.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015711
003      
CZ-PrNML
005      
20250731091200.0
007      
ta
008      
250708e20250519sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/ti.2025.14312 $2 doi
035    __
$a (PubMed)40458542
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Viklicky, Ondrej $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Transplantation Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czechia
245    10
$a 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study / $c O. Viklicky, I. Zahradka, J. Mares, J. Slatinska, A. Parikova, V. Petr, M. Roder, K. Jaklova, K. Osickova, L. Janousek, P. Hruba
520    9_
$a Intravenous immunoglobulins (IVIG) are commonly used in peri-transplant desensitization, but evidence supporting their efficacy is limited. We conducted a prospective, randomized single-center, open-label, Phase IIIb non-inferiority clinical pilot trial to compare the efficacy of IVIG (administered at a dose of 3 × 0.5 g/kg) versus no IVIG, in conjunction with rabbit anti-thymocyte globulin (5-7 mg/kg) induction, in pre-sensitized patients with donor-specific antibodies who had negative pre-transplantation Flow- and CDC-crossmatches, between July 2020 and November 2022. The primary endpoint was the rate of efficacy failure, defined as biopsy-proven rejection within 12-month post-transplant. Secondary endpoints included the incidence of rejection at protocol biopsies, evaluated by histology and biopsy-based transcripts diagnostics. Of the screened patients, 53 (72.6%) were excluded due to crossmatch positivity. Ten patients were randomized to the IVIG+, and 7 to the IVIG-arm. The trial was prematurely terminated due to futility at interim analysis. In the IVIG-arm, 3 patients (43%) experienced the primary endpoint compared to none in the IVIG+ arm (p = 0.026). MMDx identified one molecular ABMR in the IVIG+ and 2 in the IVIG-arm in 12-month protocol biopsies. There was one graft loss in the IVIG-arm. The results of this pilot study, although not definitive, do not support the use of IVIG-sparing regimens in HLA-incompatible kidney transplantation (NCT04302805). This study is registered on ClinicalTrials.gov under the identifier NCT04302805.
650    _2
$a dospělí $7 D000328
650    _2
$a zvířata $7 D000818
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a antilymfocytární sérum $x aplikace a dávkování $7 D000961
650    12
$a desenzibilizace imunologická $x metody $7 D003888
650    12
$a rejekce štěpu $x prevence a kontrola $x imunologie $7 D006084
650    12
$a intravenózní imunoglobuliny $x aplikace a dávkování $7 D016756
650    12
$a transplantace ledvin $x škodlivé účinky $7 D016030
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
700    1_
$a Zahradka, Ivan $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Mares, Jan $u Department of Data Science, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Slatinska, Janka $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Parikova, Alena $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Petr, Vojtech $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Roder, Matej $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Jaklova, Katerina $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Osickova, Klara $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Janousek, Libor $u Department of Transplantation Surgery, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Hruba, Petra $u Transplantation Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czechia
773    0_
$w MED00004553 $t Transplant international $x 1432-2277 $g Roč. 38 (20250519), s. 14312
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40458542 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091154 $b ABA008
999    __
$a ok $b bmc $g 2366513 $s 1252836
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 38 $c - $d 14312 $e 20250519 $i 1432-2277 $m Transplant international $n Transpl Int $x MED00004553
LZP    __
$a Pubmed-20250708
Back

Find record

Citation metrics

Archiving options